{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Etaracizumab",
  "nciThesaurus": {
    "casRegistry": "892553-42-3",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A humanized monoclonal IgG1 antibody directed against the vitronectin receptor alpha v beta 3 integrin. Etaracizumab blocks the binding of ligands, such as vitronectin, to alpha v beta 3 integrin, resulting in inhibition of angiogenesis and metastasis. Alpha v beta 3 integrin is a cell adhesion and signaling receptor that is expressed on the surface of tumor vessel endothelial cells, some tumor cells, and a number of other cell types.",
    "fdaUniiCode": "41W9MFI160",
    "identifier": "C1800",
    "preferredName": "Etaracizumab",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C129822",
      "C20401"
    ],
    "synonyms": [
      "Abegrin",
      "ETARACIZUMAB",
      "Etaracizumab",
      "Humanized Monoclonal Antibody LM609",
      "MEDI-522",
      "Monoclonal Antibody Anti-Avb3 Integrin Medi-522",
      "Monoclonal Antibody Anti-alpha V Beta 3 Integrin MEDI-522",
      "Vitaxin",
      "etaracizumab",
      "humanized monoclonal antibody MEDI-522"
    ]
  }
}